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P H Y S I O L O G Y
Reduced MC4R signaling alters nociceptive thresholds 
associated with red hair
Kathleen C. Robinson1*, Lajos V. Kemény1*, Gillian L. Fell1†, Andrea L. Hermann1,2, 
Jennifer Allouche1, Weihua Ding3, Ajay Yekkirala4, Jennifer J. Hsiao1, Mack Y. Su1, 
Nicholas Theodosakis1, Gabor Kozak5,6, Yuichi Takeuchi5,7,8,9, Shiqian Shen3, 
Antal Berenyi5,8,10,11, Jianren Mao3, Clifford J. Woolf4, David E. Fisher1‡
Humans and mice with natural red hair have elevated basal pain thresholds and an increased sensitivity to opioid 
analgesics. We investigated the mechanisms responsible for higher nociceptive thresholds in red-haired mice 
resulting from a loss of melanocortin 1 receptor (MC1R) function and found that the increased thresholds are 
melanocyte dependent but melanin independent. MC1R loss of function decreases melanocytic proopiomelanocortin 
transcription and systemic melanocyte-stimulating hormone (MSH) levels in the plasma of red-haired (Mc1re/e) 
mice. Decreased peripheral -MSH derepresses the central opioid tone mediated by the opioid receptor OPRM1, 
resulting in increased nociceptive thresholds. We identified MC4R as the MSH-responsive receptor that opposes 
OPRM1 signaling and the periaqueductal gray area in the brainstem as a central area of opioid/melanocortin an-
tagonism. This work highlights the physiologic role of melanocytic MC1R and circulating melanocortins in the 
regulation of nociception and provides a mechanistic framework for altered opioid signaling and pain sensitivity 
in red-haired individuals.
INTRODUCTION
Humans and mice with red hair exhibit altered pain thresholds, in-
creased nonopioid analgesic requirements, and enhanced responses 
to opioid analgesics (1–6). Red hair in both species is caused by loss-
of-function variant alleles of the melanocortin 1 receptor (MC1R), 
a Gs-coupled receptor expressed on melanocytes, the pigment- 
producing cells of the skin (7). MC1R mutant red-haired mice are 
less sensitive to noxious thermal, mechanical, and chemical stimuli 
(4). However, the mechanism of this altered nociception has not 
been determined, prompting us to examine the mechanistic con-
nection between MC1R and the modulation of nociception.
MC1R function is suppressed in the Mc1re/e mouse strain because 
of a frameshift mutation resulting in a premature stop codon. This 
strain (referred to herein as red-haired mice) has yellow/red hair 
and recapitulates features of red-haired humans including synthesis 
of red/blond pheomelanin pigment, inability to tan following UV 
exposure, and increased ultraviolet (UV)–associated skin cancer 
risk (8, 9).
RESULTS
To initially assess nociceptive thresholds in Mc1re/e mice in a blind-
ed fashion and to test the role of pigment (versus red-haired genetic 
background) in nociception, we crossed Mc1re/e mice with an albino 
strain containing a loss-of-function mutation in the tyrosinase gene 
(Tyrc/c). In these mice, melanocyte numbers are not altered, but they 
are unpigmented (fig. S1). Double mutant Mc1re/e;Tyrc/c mice are 
visually indistinguishable from Tyrc/c mice, as both have white hair. 
After “unblinding” the measurements, mice homozygous for the red 
hair allele (Mc1re/e) exhibited significantly higher nociceptive thresh-
olds for both pressure and temperature relative to Mc1rE/E wild-type 
(WT) mice in the albino genetic background (Tyrc/c) (Fig. 1, A and 
B). Similarly, increased nociceptive thresholds were observed for 
Mc1re/e mice compared with Mc1rE/E mice in the non-albino Tyr+/+ 
C57BL/6J background (Fig. 1, C and D), in agreement with previ-
ous observations (4). This finding suggests a pigment-independent 
role of MC1R in the regulation of nociception.
To determine whether the increased nociceptive thresholds in red- 
haired mice are caused by MC1R loss of function within melanocytes 
or in other cell types, we compared three genetically matched (C57BL/6J) 
mouse models that differ in melanocyte numbers (summarized in 
table S1). Mice with increased numbers of epidermal melanocytes 
(K14-SCF) exhibited significantly lower nociceptive thresholds (Fig. 1, 
E and F), while mice lacking melanocytes (Mitf mi-wh/mi-wh) displayed 
higher nociceptive thresholds compared with WT mice (Fig. 1, G 
and H). These findings suggest that the number of epidermal mela-
nocytes (independent of MC1R function) can modulate nociceptive 
thresholds. Next, we crossed red-haired mice with Mitf mi-wh/mi-wh 
mice. Because Mitf mi-wh/mi-wh mice completely lack melanocytes, 
this comparison between “red-haired” Mc1re/e;Mitf mi-wh/mi-wh and 
“black-haired” Mc1rE/E;Mitf mi-wh/mi-wh groups tests potential MC1R 
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function in nonmelanocytic cells. As shown in Fig.  1 (G and H), 
genetic absence of melanocytes ablated the ability of MC1R to influ-
ence nociceptive thresholds, suggesting that altered thresholds are 
dependent on MC1R function in melanocytes rather than in other 
cell types.
One potential modulator of the elevated nociceptive threshold in 
red-haired mice is -endorphin, a posttranslational cleavage product 
of proopiomelanocortin (POMC), which is expressed in melano-
cytes (10–12). POMC is induced by adenosine 3′,5′-monophosphate 
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Fig. 1. Nociceptive thresholds and POMC production are affected by melanocyte status and MC1R signaling. Loss of function of MC1R increases mechanical and 
thermal nociceptive thresholds in C57BL/6J Tyrc/c albino mice (A and B) and in non-albino C57BL/6J mice (C and D). Nociceptive thresholds are decreased in K14-SCF strain 
compared with C57BL/6J mice measured by both von Frey assay (E) and hot plate assay (F). Mc1re/e;Mitf mi-wh/mi-wh double mutants had increased thresholds compared 
with C57BL/6J, but similar to Mitf mi-wh/mi-wh, by von Frey (G) and hot plate assays (H). (I) Levels of -endorphin in blood plasma were assayed by radioimmunoassay, sug-
gesting MC1R-dependent melanocytic regulation of POMC. (J) shMc1r in the mouse melanocytic Melan-C cell line decreases Pomc mRNA expression. ***P < 0.001 com-
pared with all of the shControl clones and the parental line. (K) The MC1R ligand -MSH (2 M) increases Pomc production in Melan-C cells. (L) Pomc expression is 
decreased in the epidermal skin of red K14-SCF;Mc1re/e mice compared with black K14-SCF;Mc1rWT mice. Graphs show means ± SEM; numbers in parentheses = n per 
group. Data shown in (C) and (D) represent compilations of baseline thresholds from all black and red-haired male mice in the C57BL/6J background used in the study. 
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mutant melanocytes may affect POMC expression. Red-haired (Mc1re/e) 
mice had significantly lower plasma levels of -endorphin than ge-
netically matched black (C57BL/6J WT) mice (Fig. 1I). However, 
this difference did not suggest that changes in -endorphin mediate 
altered nociceptive thresholds because the direction of change is 
opposite from the phenotypic change, since opioid signaling pro-
motes rather than diminishes analgesia. Moreover, plasma levels of 
-endorphin were also inversely associated with nociceptive thresh-
olds in K14-SCF mice (higher melanocyte numbers and lower noci-
ceptive thresholds) and Mitf mi-wh/mi-wh mice (absent melanocytes 
and higher nociceptive thresholds). Collectively, these data demon-
strated a consistent pattern in which melanocyte numbers (K14-SCF, 
Mitf mi-wh/mi-wh) and function (Mc1rE/E, Mc1re/e) were inversely cor-
related with nociceptive thresholds despite being directly related to 
circulating -endorphin levels.
To test for a direct role of melanocytes in modulating POMC 
expression downstream of MC1R, we knocked down Mc1r mRNA 
(Fig. 1J) or stimulated MC1R with –melanocyte-stimulating hor-
mone (-MSH) (Fig.  1K) in the mouse melanocyte line Melan-C 
(15) and observed decreased and increased Pomc mRNA produc-
tion, respectively. Furthermore, isolated epidermal RNA from black 
(K14-SCF;Mc1rE/E) and red-haired (K14-SCF;Mc1re/e) mice revealed 
reduced Pomc expression in epidermal skin of mice harboring loss 
of function in MC1R (Fig. 1L), similar to the lower plasma levels of 
circulating -endorphin in the red-haired background (Fig. 1I, top). 
Pomc expression did not show statistically significant reduction in 
the adrenal gland and in the pituitary gland of Mc1re/e mice (fig. S2), 
suggesting that the plasma level alterations of POMC in this genetic 
background are mainly due to the decrease in melanocytic Pomc 
production caused by loss of Mc1r function.
To determine whether the elevated nociceptive thresholds were 
a result of compensation for or adaptation to the lower -endorphin 
levels, we used two genetic models: mice carrying homozygous 
POMC mutation that expresses all melanocortin peptides but lacks 
the terminal -endorphin sequence (“-endorphin knockout”) and 
a strain deficient in the -endorphin receptor gene, -opioid receptor 
(Oprm1−/−). We observed no measurable effect of -endorphin 
knockout on the nociceptive threshold differences in black versus 
red-haired mice (Fig. 2, A and B), suggesting that -endorphin ex-
pression does not account for the altered nociceptive thresholds, as 
anticipated because its levels were inversely related to phenotypes. 
Oprm1 deletion had no effect on nociceptive thresholds in black 
mice, in agreement with previous observations (16,  17) and sup-
porting the hypothesis that basal nociceptive thresholds in WT 
C57BL/6 mice are unaffected by endogenous opioids (18, 19). How-
ever, the absence of OPRM1 abolished the elevated thresholds in 
red-haired mice (Fig. 2, C and D). Similarly, naloxone, a broad opi-
oid receptor antagonist (20), and cyprodime, an antagonist specific 
for the -opioid receptor (21), both significantly reduced nocicep-
tive thresholds in red-haired mice to levels in black mice or to even 
lower levels at high doses (Fig. 2, E and F). A decrease below WT 
levels was observed only with pharmacologic antagonists and may 
reflect a difference between acute blockade and chronic absence of 
signaling.
These findings suggest that the elevated nociceptive thresholds 
in red-haired mice are mediated by, and dependent on, -endorphin–
independent opioid receptor signaling. We also observed a decrease 
in nociceptive thresholds when Mitf mi-wh/mi-wh mice (devoid of me-
lanocytes) were treated with naloxone (Fig. 2G), consistent with a 
common endogenous opioid-dependent mechanism for Mitf mi-wh/mi-wh 
and red-haired Mc1re/e mice.
We reasoned that higher -opioid receptor signaling in the pres-
ence of low plasma levels of -endorphin could be explained by 
up-regulation of another endogenous opioid, an adaptation of the 
-opioid receptor, or reduction of a pathway that antagonizes opi-
oid signaling. Direct measurements of the circulating opioid ligands 
dynorphin, enkephalin, and endomorphin revealed no significant 
differences between red-haired and black mice (Fig. 3, A to C). Giv-
en previously published data (2) on differences between red-haired 
and black mice in their response to pentazocine, a -opioid receptor 
agonist, we chose to further examine the  receptor agonist dynor-
phin. We crossed a dynorphin knockout strain with red-haired and 
black mice but did not observe measurable effects on nociceptive 
thresholds in red-haired or black genetic backgrounds (Fig.  3,  D 
and E). These data suggest that elevation of an endogenous opioid 
is unlikely to be responsible for the increased nociceptive threshold 
in the red hair background.
Pharmacologic manipulation of the melanocortin pathway an-
tagonizes certain effects of morphine (22, 23), leading us to examine 
plasma levels of MSH (melanocortin agonist), which, like -endorphin, 
is also encoded within POMC. We observed that plasma -MSH levels 
varied significantly across mice of different pigmentation pheno-
types, paralleling -endorphin levels as anticipated given their com-
mon POMC precursor, with higher -MSH levels in mice with more 
melanocytes or WT MC1R/black pigmentation (Fig. 4A) and lower 
in mice with fewer melanocytes or red-haired genetic background. 
Plasma -MSH levels therefore vary in a manner that is consistent 
with and might be responsible for the observed nociceptive pheno-
types, unlike -endorphin that is inversely related. Given that 
-MSH [or its larger parent peptide adrenocorticotropic hormone 
(ACTH)] represents the only known melanocortin ligand, whereas 
-endorphin is one of multiple endogenous ligands capable of acti-
vating -opioid receptor signaling, a decrease in both -MSH and 
-endorphin might result in a net increase in opioid signaling sus-
tained by non–POMC-derived opioid ligands. To functionally evaluate 
whether proportionally low -MSH may contribute to the elevated 
nociceptive thresholds in the red hair background, we first rescued 
low endogenous -MSH levels in red-haired mice pharmacologically. 
We observed that an -MSH peptide mimic, melanotan II, de-
creased nociceptive thresholds in a dose-dependent fashion in male 
red-haired Mc1re/e mice but not in black Mc1rE/E mice (Fig.  4B). 
Second, given the sex-dependent role of Mc1r in mediating phar-
macologic -opioid analgesia (2), we repeated these experiments in 
female red-haired Mc1re/e mice and observed the same patterns as 
in male red-haired Mc1re/e mice (fig. S3, A to D). These results sug-
gest that loss of function in MC1R signaling results in increased 
nociceptive thresholds because of melanocortin deficiency in a sex- 
independent (likely -opioid–independent) manner. As the MSH 
mimic-induced rescue phenotype occurred in red-haired mice car-
rying MC1R deficiency (as a result of an Mc1r frameshift mutation), 
it suggested that an MSH receptor other than MC1R is the likeliest 
mediator of the altered nociception (and opioid antagonism).
Another melanocortin receptor, MC4R, and its inhibition have 
been implicated in pharmacologic analgesia and neuropathic pain 
(23, 24). We initially tested the peptide SHU 9119, which antagoniz-
es MC4R and MC3R while being an agonist for MC1R and MC5R 
(25). SHU 9119 produced analgesia when injected into male black 
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in K14-SCF;Mc1re/e mice, which have levels of POMC products (fig. 
S3) and nociceptive thresholds similar to black WT mice (Fig. 4C) 
but lack MC1R function, injection of SHU 9119 increased nocicep-
tive thresholds. These functional results suggested that the analgesic 
effects of SHU 9119 are Mc1r independent and likely due to ligand 
effects on MC4R or MC3R, consistent with the possibility that MC4R 
or MC3R signaling may balance opioid signaling to modulate noci-
ceptive thresholds.
To explore whether MC4R plays a functional role in regulating 







































































































































































































































Fig. 2. Elevated nociceptive thresholds in red-haired mice depend on opioid signaling but not -endorphin. -Endorphin deletion has no effect on mechanical 
(A) or thermal (B) nociceptive thresholds in either black or red-haired mice (compilations of two independent experiments). Deletion of the -opioid receptor did not 
affect nociceptive thresholds in black mice but abolished the increased thresholds in red-haired mice in both mechanical (C) and thermal (D) nociception assays. (E) Nalox-
one treatment (10 mg/kg, intraperitoneally) abolished the increased nociceptive threshold of red mice. (F) Cyprodime treatment showed a dose-dependent effect on 
thermal nociception in red-haired, but not black, mice (for Mc1rWT, n = 11, except n = 10 for 0.0064 mg/kg; for Mc1re/e, n = 9, except n = 7 for 9.6 mg/kg). (G) Naloxone 
treatment also decreased nociceptive thresholds in Mitf mi-wh/mi-wh homozygous mice (n = 8 per group). For (A) to (D), the investigator performing the experiment was 
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they exhibit elevated nociceptive thresholds (Fig. 4, D and E). The 
absence of MC4R (on a genetically black Mc1rE/E background) also 
resulted in sensitivity to opioid antagonism (Fig.  4F), resembling 
red-haired Mc1re/e mice and suggesting that the nociceptive thresh-
old may be determined by a balance between OPRM1 and MC4R 
signaling. We also repeated this experiment using naloxonazine, a 
specific antagonist for the -opioid receptor, and found that phar-
macologic inhibition of OPRM1 is sufficient to restore nociceptive 
thresholds in both Mc4r null and Mc1re/e mice (Fig. 4G). Further-
more, melanocortin agonist treatment reduced the elevated noci-
ceptive thresholds in red-haired mice (Fig. 4B) but had no effect on 
nociception in Mc4r null mice (Fig. 4H), suggesting that MC4R is 
the key melanocortin receptor upon which MSH acts as a ligand for 
nociceptive threshold reduction.
We hypothesized that if MSH deficiency in Mc1re/e mice is act-
ing through MC4R, then Mc1re/e;MC4R−/− mice should have similar 
nociception to Mc1re/e and MC4R null mice. When we generated 
Mc1re/e;MC4R−/− mice, we found that Mc1re/e;MC4R−/− mice have 
similar nociception to Mc1re/e and MC4R−/− mice (Fig. 4I), suggest-
ing that there is a similar underlying mechanism responsible for the 
elevated nociceptive thresholds in these genetic mouse models.
Next, we asked whether the site of the opioid/melanocortin an-
tagonism modulating nociception is central or peripheral. The no-
ciceptive difference observed between black and red-haired mice 
was diminished after peripheral (intraperitoneal) administration of 
naltrexone, an opioid receptor antagonist that is able to cross the 
blood-brain barrier (BBB) (Fig. 5A). However, peripheral adminis-
tration of methylated naltrexone, a BBB-impermeable opioid antagonist, 
did not diminish the nociceptive differences between black and red-
haired mice (Fig. 5B), suggesting minimal peripheral influence. This 
suggests that the relative increase in opioid signaling in red-haired 
mice occurs centrally, not peripherally, and highlights the impor-
tance of -MSH in balancing opioid receptor–mediated regulation 
of central nociception.
Previous studies have demonstrated a role for cAMP signaling in 
modulating opioid analgesia (26). We therefore measured the im-
pact of antagonism between melanocortin and opioid signaling on 
cAMP content in rat primary hypothalamic neurons (RPHNs). We 
observed that the melanocortin agonist [Nle4,D-Phe7]--MSH in-
creased cAMP content, whereas the opioid agonist morphine sig-
nificantly inhibited melanocortin-induced cAMP elevation (Fig. 5C), 
consistent with previous observations (27). These data suggest that 
melanocortin and opioid signaling may antagonize each other in a 
cell-autonomous manner.
Costaining MC4R-GFP (green fluorescent protein) neurons with 
OPRM1 in mice has suggested the existence of neurons expressing 
both receptors in the periaqueductal gray area (PAG) (28). First, we 
measured the mRNA levels of opioid receptors in the PAG in differ-
ent genetic backgrounds and found no significant alterations in the 
opioid receptors in the PAG in Mc1re/e and Mc4r−/ mice (fig. S5). 
We next investigated the potential role of the PAG in modulating 
nociception and found that local antagonism of opioid receptors by 
naloxone, by the -opioid receptor–specific naloxonazine (29), or 
agonism of melanocortin receptors (independently of Mc1r) in 
PAG-cannulated Mc1re/e mice significantly decreases nociceptive 
thresholds (Fig. 5D). To further investigate the localization of MC4R 
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Fig. 3. Low levels of -endorphin are not compensated by other endogenous opioids. (A to C) Plasma levels of dynorphin, enkephalin, and endomorphin are un-
changed in red versus black mice. (D and E) Loss of the dynorphin gene (Dyn−/−) has no effect on nociceptive thresholds in red or black mice. Graphs show means ± SEM; 
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relative to -opioid receptors in the central nervous system (CNS), 
we analyzed publicly available transcriptomic data (“brain atlas”) 
from six postmortem human brains (30) and identified multiple ad-
ditional regions showing enrichment for both MC4R and OPRM1 
(fig. S6), some of which have been associated with the regulation of 
pain (31–34). We also investigated the possible correlation between 
MC4R and OPRM1 across brain regions and patients and found a 
slight positive correlation (figs. S7 and S8) in the posterior group of 
nuclei; however, these analyses are limited by the small number of 
available datapoints. Corroborating these human data, we stained 
for both OPRM1 and MC4R proteins in rat brains and found costain-
ing in several regions corresponding to the human brain regions 
where we observed coexpression of MC4R and OPRM1 mRNAs 
(fig. S9). It should be noted that MC4R antibodies have certain lim-
itations. We tested multiple commercially available antibodies and 
used an antibody that showed the best signal-to-noise ratio in the 
arcuate nucleus (fig. S10). These results are consistent with the pos-
sibility that melanocortin and opioid signaling may antagonize 
each other in a cell-autonomous manner. However, it is also possi-
ble that other indirect or non–cell-autonomous mechanisms may 
Thermal nociception
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Fig. 4. MC4R signaling regulates nociception. -MSH in blood plasma was found to be lowest in red-haired mice and Mitf mi-wh/mi-wh mice but elevated in K14-SCF mice 
(A), suggesting that melanocyte number and function are positively associated with plasma -MSH level. Treatment with a melanocortin agonist, melanotan II (0.5 mg/kg), 
reduced thermal nociceptive thresholds in red-haired mice (B) (n = 10 per group, except n = 9 for Mc1re/e saline), while nociceptive thresholds are increased by the mela-
nocortin antagonist SHU 9119 (1 g/kg) in both black and K14-SCF red-haired mice (C). (D and E) Elevated redhead nociceptive thresholds are mimicked in Mc4r null mice 
in both mechanical and thermal nociception assays. These elevated thresholds are sensitive to naloxone (F) and naloxonazine (G) but, unlike in red-haired Mc1re/e mice 
(B), cannot be decreased by melanocortin rescue with melanotan II (H). (I) Elevated nociceptive thresholds are not restored by genetic deletion of Mc4r in Mc1re/e back-
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additionally contribute to increased opioid tone in red-haired Mc1re/e 
mice. For example, heterodimerization of G protein–coupled receptors 
can affect receptor function (35) and OPRM1 has been previously 
shown to interact with MC3R (36); therefore, it is possible that for-
mation of different heterodimers might also contribute to the in-
creased opioid tone. However, Mc1re/e;MC4R−/− mice have similar 
nociceptive thresholds to Mc1re/e mice (Fig. 4I), suggesting that ex-
pression of MC4R is not required for maintenance of increased no-
ciceptive thresholds in this background. Therefore, the possible 
involvement of OPRM1/MC4R heterodimerization is unlikely to be 
solely responsible for the elevated nociceptive thresholds in the red-
haired genetic backgrounds.
The data presented here suggest that elevated nociceptive thresh-
olds found in the red-haired genetic background arise from a reduc-
tion in -MSH levels caused by decreased POMC production in 
melanocytes, resulting in diminished MC4R signaling. Lower MC4R 
signaling, in turn, decreases its antagonism of opioid signaling within 
the CNS, which, despite diminished -endorphin production, ex-
hibits no discernible differences in other endogenous opioid ligands 
in the red hair background. Collectively, this produces a net mela-
nocortin deficiency relative to opioid signaling, which alters the bal-
ance in favor of -opioid receptor–induced analgesia within the red 
hair background (illustrated in Fig. 5E).
DISCUSSION
Our observations regarding high nociceptive thresholds in red-haired 
Mc1re/e mice match previous findings of genotype-driven and sex-
i ndependent human and mouse nociceptive patterns (4). Also, it 
should be noted that despite the occasional minor variability in 
baseline nociceptive measurements (for example, Fig. 4, E and F), 
we consistently observed a significant difference between black and 
red-haired mice, suggesting that the differences are much more ro-
bust than the minor fluctuations caused by other environmental/
technical factors. We provide mechanistic insights for these differ-
ential nociceptive thresholds by identifying the role of MC1R variant 
(red-hair) loss of function in altering the balance of physiologic an-
tagonism between OPRM1 and MC4R through decreased plasma 
MSH. However, other mechanisms could also contribute to the ob-
served differences. Heterodimerization of OPRM1 with melanocortin 
receptors (possibly MC3) (36) or additional sex-dependent mecha-
nisms could also contribute to the nociceptive differences observed 
in melanocortin-deficient mice. Alternatively, melanocortin signaling 
may directly influence nociception by modifying basal OPRM1 re-
ceptor activities such as ion channel activities, G protein coupling, 
or cAMP inhibition. These possibilities warrant future investigations.
A recent study suggests that only a few polymorphisms in the 
MC1R coding region predict a differential sensitivity to pain (37). It 
is possible that although these variants would result in decreased 
MC1R function (as evidenced by red hair), the loss of function may 
not impair POMC production in these patients or POMC levels 
might be somehow compensated through other mechanisms. How-
ever, it is challenging to study POMC levels in human populations 
that can significantly differ in UV shielding due to varying levels of 
pigmentation and that are exposed to various levels of UV radia-
tion; therefore, the effect of MC1R coding variants on melanocytic 
POMC expression requires further in-depth examination. It is also 
possible that in humans, MC1R might regulate POMC in nonmela-
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Fig. 5. Increased central opioid tone regulates basal nociception in red-haired 
mice. Blood-brain barrier (BBB)–impermeable methylnaltrexone (10 mg/kg) can-
not reverse increased nociception in red Mc1re/e mice when injected peripherally 
(A) (n = 20 for all groups), whereas BBB-permeable naltrexone (10 mg/kg) can (B) (n = 20 
per group), suggesting the involvement of CNS regions in the increased noci-
ception. (C) In line with the coexpression of MC4R and OPRM1, melanocortin and 
opioid signaling can antagonistically modulate cAMP levels in primary rat hypo-
thalamic neurons. DMSO, dimethyl sulfoxide. (D) Local administration of naloxone, 
naloxonazine, or melanotan to the periaqueductal gray area (PAG) reduces noci-
ceptive thresholds in red Mc1re/e mice (n = 9 using the same mice for all treat-
ments). (E) Summary of the antagonistic opioid-melanocortin model in black and 
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Our study does not distinguish between transcript level–reducing 
variants and MC1R activity variants, and it is possible that those 
variants might differentially regulate POMC in mouse and human 
melanocytes, as hypothesized by Zorina-Lichtenwalter et al. (37). 
However, we have demonstrated that the number of melanocytes 
also regulates basal nociception, suggesting that besides the loss 
of MC1R function (as in Mc1re/e mice), the absolute number of me-
lanocytes is also an important determinant in nociception. The 
question of whether the MC1R level altering variations that are 
associated with differential nociception in humans would also phe-
nocopy the MC1R function loss in mouse models remains to be 
explored.
POMC induction causes -endorphin–mediated analgesia after 
UV exposure (38), whereas in the absence of UV exposure, a reduction 
in POMC results in melanocortin deficiency–mediated analgesia, as 
reported here. That both an increase and decrease in POMC can 
increase analgesia reflects the circumstance wherein a single gene 
encodes different peptides that activate two opposing pathways. The 
net effect of POMC depends on the balance of signaling between 
these two pathways and appears to be affected by differences in basal 
activities and the presence of other (non–POMC-derived) endoge-
nous ligands. In the red hair background, the decrease in MC4R ligands 
with low POMC is proportionally large (as MC4R has no known 
ligands beyond POMC-derived MSH/ACTH) relative to -opioid 
receptor ligands where dynorphin, endomorphin, and enkephalin 
are unchanged (illustrated in Fig. 5E).
While our study focuses on the red hair phenotype, the underly-
ing melanocortin/opioid signaling balance may also account for pain 
variations among non–red-haired individuals. For example, we ob-
served that Mc4r null mice exhibit high nociceptive thresholds like 
Mc1re/e mice, but are not red haired, reflecting an alternative means 
to alter the melanocortin-opioid balance. Individuals with MC4R 
polymorphisms may also have elevated pain thresholds and altered 
sensitivities to analgesics similar to those reported in red-haired in-
dividuals (4). This study has revealed previously unknown and 
unexpected insights into the molecular and signaling determinants 
of basal nociceptive thresholds.
MATERIALS AND METHODS
Mice
All experiments were performed with male mice at least 8 weeks of 
age, with the exception that female mice were used in the experiments 
of fig. S3. Mice were bred on site. All experiments were performed 
with approval from the Massachusetts General Hospital Institu-
tional Animal Care and Use Committee. All mice used were on the 
C57BL/6J background or had been backcrossed to the C57BL/6J 
background at least 10 generations, except for the Mc4r−/− strain, 
which was developed on the 129S background and backcrossed 
with C57BL/6J for only one generation. However, Mc4r−/− mice were 
visually indistinguishable from mice on the C57BL/6J background, 
making blind experiments possible. Mc1re/e, Tyrc/c, -endorphin−/−, 
Dynorphin−/−, Mc4r−/−, and Oprm1−/− mice were obtained from The 
Jackson Laboratory (39, 40, 16, 41–43). The K14-SCF strain was a 
gift from T. Kunisada (44), whereas Mitf mi-wh/mi-wh mice were a gift 
from N. Jenkins (45). Mice were used for single experiments, except 
the same groups of mice were used for measuring thermal and me-
chanical nociception and for the effects of different pharmacological 
compounds.
Drugs
Naloxone hydrochloride (N7758), naltrexone hydrochloride (N3136), 
and melanotan II acetate salt (M8693) were purchased from Sigma- 
Aldrich; SHU 9119 (NC9447656), cyprodime hydrochloride 
(NC9079878), naloxonazine hydrochloride (059110), and DAMGO 
(11711) were from Thermo Fisher Scientific; and methylnaltrexone 
bromide (787933) was from McKesson. Morphine was obtained 
from Patterson Veterinary #078924699. All drug administrations to 
mice were by intraperitoneal injection.
Nociceptive testing
The hot plate assay was performed as originally described (46) on a 
52°C hot plate with a maximum cutoff time of 20 s, except for the 
experiments using Mitf mi-wh/mi-wh, where a cutoff of 30 s was used to 
enable detecting additive effects of the incorporation of the Mc1re/e 
allele. The von Frey assay was performed as described previously 
(47). Where possible, the investigator was blinded to the genotypes 
of the mice.
PAG cannulation
For cannulation, mice underwent isoflurane anesthesia. Cannulas 
were positioned to target the ventral lateral PAG (coordinates used 
bregma −4.5 mm and lateral 0.5 mm) with a custom-made infusion 
system (P1 Technologies, VA, USA). Custom-made guide cannulas 
were cut at 2.2-mm length. For intra-PAG injections, an internal can-
nula of 2.5-mm length was used to administer phosphate-buffered 
saline (PBS), naloxone, or melanotan under isoflurane anesthesia in 
2-l volume. Nociceptive thresholds were then measured using the 
hot plate assay. The same animals were used to test all pharmaco-
logic agents for this experiment.
mRNA enrichment analysis
Enrichment analyses of MC4R and OPRM1 in human postmortem 
brain transcriptomic profiles were performed as described previously 
(48). Briefly, transcriptomic profiles of six postmortem human brains 
were downloaded from the Allen Human Brain Atlas (30) in May 
2017. To identify brain regions enriched for OPRM1 and MC4R, 
190 regions that had transcriptomic profiles from at least four pa-
tients were used. We averaged MC4R and OPRM1 expression per 
region per patient and performed z transformation. The obtained z 
values indicate the difference in number of SDs for expression in an 
individual brain region compared with the average expression 
across all regions. For OPRM1 and MC4R, we considered a z value 
of ≥1 to be enriched.
Epidermal RNA isolation
Black K14-SCF;Mc1rE/E and red K14-SCF;Mc1re/e mice were eutha-
nized by cervical dislocation. Epidermis was isolated from the ears 
of the animals after dispase digestion for 3 hours at 37°C. Two ears 
from each mouse were pooled.
Cell culture
Melan-C cells were grown in Ham’s F-10 medium supplemented 
with 10% fetal bovine serum and 1% penicillin/streptomycin. Cells 
were serum-starved for various lengths of time before adding 2 M 
-MSH (Phoenix Pharmaceuticals Inc., #043-01), and then RNA 
was harvested from all samples at the same time 25 hours after ini-










Robinson et al., Sci. Adv. 2021; 7 : eabd1310     2 April 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
9 of 11
MC1R knockdown and single clone isolation
Lentivirus was generated in 293T cells. Cells were transfected using 
250 ng of vesicular stomatitis virus glycoprotein, 1250 ng of the plasmid 
PsPAX2, and 1250 ng of luciferase short hairpin RNA (shRNA) (control) 
or Mc1r shRNA. Melan-C cells were plated the day before transduction. 
After transduction with lentivirus, plates were centrifuged at 3000 rpm 
for 30 min at 37°C. Transduced cells were selected with 1:1000 pu-
romycin (Thermo Fisher Scientific, catalog no. NC9138068). Single-cell 
clones were picked up using Scienceware 3.2-mm-diameter cloning 
discs (Sigma-Aldrich). Mc1r shRNA sequences: shMc1r1, CATC-
CCTTCCTGATCTCCATT; shMc1r2, CGTCACTTTCTTTCTAG-




For quantitative reverse transcription polymerase chain reactions 
(qRT-PCRs), the forward and reverse primers for Pomc were AA-
GAGGCTAGAGGTCATCAG and AGAACGCCATCATCAAGAAC, 
for OPRM1 CAGGGCTTGTCCTTGTAAGAAA and GACTCGG-
TAGGCTGTAACTGA, for OPRD ATGGCCTCATGCTACTGCG 
and CACCAGCGTCCAGACGATG, for OPRK TCCCCAACTG-
GGCAGAATC and GACAGCGGTGATGATAACAGG, for 18S 
AGGTTCTGGCCAACGGTCTAG and CCCTCTATGGGCTC-
GAATTTT, for Actb GGCTGTATTCCCCTCCATCG and CCA-
GTTGGTAACAATGCCATGT, and for Hprt1 TCAGTCAACGGG 
GGACATAAA and GGGGCTGTACTGCTTAACCAG. KAPA 
SYBR FAST One-Step qRT-PCR (KK4651, Kapa Biosystems) was 
used for qRT-PCR assays. For quantifying Pomc mRNA expression, 
Pomc levels in ear epidermal samples were normalized to the aver-
age of 18S, Atcb, and Hprt1 to minimize variation.
For measuring levels of opioid receptors in the PAG, micro-
punches were obtained from freshly isolated PAG tissues. After cer-
vical dislocation, brains were removed in ice-cold PBS. Micropunches 
(1.5 mm wide) were then obtained, and RNA was isolated as previ-
ously described (49).
cAMP measurements
RPHNs (Lonza, R-HTH-507) were seeded in poly-d-lysine– and 
laminin-coated wells at a density of 50,000 cells per well. RPHNs 
were cultured in primary neuron growth medium (Lonza, CC-3256) 
containing growth supplements (Lonza, CC-4462). Medium was 
changed every 48 to 96 hours. On day 11 after seeding cells, serum 
starvation was performed for 30 min, and then cells were treated 
first with either 1 M DAMGO or PBS for 7.5 min and then with 
either 1 M [Nle4,D-Phe7]--MSH (M8764, Sigma-Aldrich) or wa-
ter (vehicle control) for 10 min. Cells were incubated at 37°C during 
treatments. Ten minutes after [Nle4,D-Phe7]--MSH or water treat-
ment, cells were lysed and processed for cAMP measurements with 
cAMP-GLO Assay (V1501, Promega, WI, USA) according to the 
manufacturer’s instructions.
Radioimmunoassays
Plasma levels of -MSH (RK-043-01), -endorphin (RK-022-06), 
enkephalin-leucine (RK-024-21), endomorphin-1 (RK-044-10), 
and dynorphin (RK-021-03) were measured using radioimmunoas-
say kits (Phoenix Pharmaceuticals Inc., CA, USA) as described pre-
viously (38). The specificities of the kits were determined by the 
manufacturer.
Histology
All histology experiments were performed in accordance with 
European Union guidelines (2003/65/CE) and were approved by the 
Ethical Committee for Animal Research at the Albert Szent-Györgyi 
Medical and Pharmaceutical Center of the University of Szeged.
MC4R and OPRM1 double immunohistochemistry
Three male Long-Evans rats (450 to 600 g) were anesthetized with 4 to 
5% isoflurane followed by urethane (1.5 g/kg) injection (intraperi-
toneally) and then transcardially perfused with physiological saline 
followed by 4% paraformaldehyde and 0.2% picric acid in 0.1  M 
phosphate buffer (pH 7.2 to 7.3). After removal, brains were post-
fixed overnight, embedded in 4% agarose, coronally sectioned at 40-m 
thickness using a vibrating blade microtome, and harvested in 0.1 M 
PBS. The following staining procedure was performed at room tem-
perature. All incubations were followed by washing with 0.1 M PBS 
containing 0.3% Triton X-100 (PBS-X). Sections were incubated 
successively with 10% normal donkey serum (NDS) in PBS-X for 
30 min, a mixture of primary antibodies rabbit anti-MC4R at 1:250 
(Alomone Labs, catalog no. AMR-024, RRID:AB_2039980) and guinea 
pig anti-OPRM1 at 1:500 (Abcam, catalog no. ab64746, RRID:AB_ 
1141103) (50) in PBS-X containing 1% NDS (PBS-XD) for 48 hours, and 
then a mixture of secondary antibodies Alexa Fluor 555–conjugated 
donkey anti-rabbit immunoglobulin G (IgG) (2 g/ml) (Thermo 
Fisher Scientific, catalog no. A-31572) and Alexa Fluor 647–conjugated 
donkey anti–guinea pig IgG (2 g/ml) (EMD Millipore, catalog no. 
AP193SA6) in PBS-XD for 2 hours. Sections were then counterstained 
with a fluoro-Nissl solution (Thermo Fisher Scientific, catalog no. 
N-21479), mounted on gelatin-coated glass slides, and coverslipped 
with 50% glycerol and 2.5% triethylene diamine in 0.1 M PBS. Cor-
pus callosum, caudate putamen, and arcuate nucleus were analyzed 
as double and single negative controls.
Confocal microscopy
Eight-bit images of stained sections were acquired using a Zeiss 
LSM880 scanning confocal microscope. Low-magnification images 
of 10-m optical thickness were acquired using a Plan-Apochromat 
20×/0.8 M27 objective lens (Carl Zeiss) with 2.06-s pixel time and 
four times frame average at 512 × 512 resolution. High-magnification 
images of 1.2-m optical thickness were acquired using an alpha 
Plan-Apochromat 63×/1.46 Oil Korr M27 objective lens with 4× 
digital zoom, 4.12-s pixel time, and 16 times frame average at 
512 × 512 resolution. Z-stack acquisitions were conducted over 10- 
to 20-m ranges at 1-m steps, each step of which was at the same 
setting as it is on the 63× objective lens. The power of the lasers was 
0.4 to 0.7 mW, which did not induce obvious fading. Acquired raw 
image files were opened and only linearly processed using a Carl 
Zeiss software (ZEN Digital Imaging for Light Microscopy, RRID:SCR_ 
013672), and each image was exported as an eight-bit jpeg file 
for display.
Statistics
For pairwise comparisons in the nociceptive assays and serum 
peptide measurements, two-tailed t tests were used. For the cAMP 
experiment and MSH time course experiment, one-way analysis of 
variance (ANOVA) was used with Dunnett’s multiple comparison 
test. For Mc1r knockdown experiments, one-way ANOVA with 
Tukey’s multiple comparison test was used. For all other experi-
ments, two-way ANOVA with Sidak’s multiple comparison test 
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a single outlier from each of two experiments: in Fig. 1L and in 
fig. S2B. For all statistical tests, Prism version 7.0a for Mac OS X 
(GraphPad Software, La Jolla, CA, USA) was used.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/14/eabd1310/DC1
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